Real-world comparison of cabozantinib versus regorafenib as second-line therapy for advanced hepatocellular carcinoma after first-line immune checkpoint inhibitors: A propensity score–matched analysis.
| Publicado en: | Journal of Clinical Oncology Vol. 44; pp. 132 - 198 |
|---|---|
| Autores principales: | , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
2026 Supplement 19
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Descripción no disponible. |